Brasofensine sulfate

Notice: hodoodo.ccom website will be shut down by June 30, 2025. Its business will be taken care by MedKoo Bioscience. Please visit medkoo.com for your research need.

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H525768

CAS#: 171655-92-8 (Brasofensine sulfate)

Description: Brasofensine sulfate, also known as NS-2214 and BMS-204756, is a dopamine reuptake inhibitor, an oral drug for Parkinson's disease.

Chemical Structure

img
Brasofensine sulfate
CAS# 171655-92-8 (Brasofensine sulfate)
Instruction

Theoretical Analysis

Hodoodo Cat#: H525768
Name: Brasofensine sulfate
CAS#: 171655-92-8 (Brasofensine sulfate)
Chemical Formula: C16H22Cl2N2O5S
Exact Mass: 0.00
Molecular Weight: 425.327
Elemental Analysis: C, 45.18; H, 5.21; Cl, 16.67; N, 6.59; O, 18.81; S, 7.54

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 171655-91-7 (Brasofensine free base)  

Synonym: Brasofensine sulfate; BMS 204756; BMS-204756; NS 2214; NS2214; NS-2214

IUPAC/Chemical Name: (E)-3-(3,4-dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carbaldehyde O-methyl oxime sulfate

InChi Key: MOYPZNPGNIZILM-NPJZCEOMSA-N

InChi Code: InChI=1S/C16H20Cl2N2O.H2O4S/c1-20-11-4-6-16(20)13(9-19-21-2)12(8-11)10-3-5-14(17)15(18)7-10;1-5(2,3)4/h3,5,7,9,11-13,16H,4,6,8H2,1-2H3;(H2,1,2,3,4)/b19-9+;/t11-,12+,13+,16+;/m0./s1

SMILES Code: O=S(O)(O)=O.CO/N=C/[C@@H]1[C@@H](C2=CC=C(Cl)C(Cl)=C2)C[C@]3([H])CC[C@@]1([H])N3C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 425.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Zhu M, Whigan DB, Chang SY, Dockens RC. Disposition and metabolism of [14C]brasofensine in rats, monkeys, and humans. Drug Metab Dispos. 2008 Jan;36(1):24-35. PubMed PMID: 17908924.

2: Pearce RK, Smith LA, Jackson MJ, Banerji T, Scheel-Krüger J, Jenner P. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets. Mov Disord. 2002 Sep;17(5):877-86. PubMed PMID: 12360536.

3: Frackiewicz EJ, Jhee SS, Shiovitz TM, Webster J, Topham C, Dockens RC, Whigan D, Salazar DE, Cutler NR. Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. Ann Pharmacother. 2002 Feb;36(2):225-30. PubMed PMID: 11847938.

4: Yu P. Brasofensine NeuroSearch. Curr Opin Investig Drugs. 2000 Dec;1(4):504-7. Review. PubMed PMID: 11249705.

5: Doudet DJ, Ruth TJ, Holden JE. Sequential versus nonsequential measurement of density and affinity of dopamine D2 receptors with [11C]raclopride: 2: effects of DAT inhibitors. J Cereb Blood Flow Metab. 2006 Jan;26(1):28-37. PubMed PMID: 15973354.

6: Minuzzi L, Olsen AK, Bender D, Arnfred S, Grant R, Danielsen EH, Cumming P. Quantitative autoradiography of ligands for dopamine receptors and transporters in brain of Göttingen minipig: comparison with results in vivo. Synapse. 2006 Mar 15;59(4):211-9. PubMed PMID: 16385509.

7: Johnston TH, Brotchie JM. Drugs in development for Parkinson's disease. Curr Opin Investig Drugs. 2004 Jul;5(7):720-6. Review. PubMed PMID: 15298067.

8: Fischman AJ, Bonab AA, Rubin RH. Regional pharmacokinetics of orally administered PET tracers. Curr Pharm Des. 2000 Nov;6(16):1625-9. PubMed PMID: 10974157.

9: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 May;25(4):317-40. PubMed PMID: 12808477.